Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Sensory Profile of People With High Intellectual Potential (HIP)

NCT07072455 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-04-01
Last updated
2026-10-30

Condition(s) studied

High Intellectual Potential

Investigational drug(s) / intervention(s)

ScalesHigh Intellectual Potential Scale

Scales: This observational study consists of data collection using a structured questionnaire based on an e-CRF, distributed by e-mail. Four questionnaires were administered : the Revised Ritvo Autism and Asperger Diagnostic Scale (RAADS-R-Fr), the Adolescent/Adult Sensory Profile (AASP), the Coping Inventory for Stressful Situations (CISS) and the State-Trait Anxiety Inventory (STAI-Y). Socio-demographic and treatments were collected.

High Intellectual Potential Scale: For participants with High Intellectual Potential, the total Intelligence Quotient (IQ) or General Ability Index (GAI), along with the index scores from the Wechsler scales (Verbal Comprehension Index, Perceptual Reasoning Index, Working Memory Index, and Processing Speed Index), will be extracted from the cognitive assessment previously completed by the participant prior to study enrollment.

Study summary

This is a prospective observational psychology study on a non-clinical population, involving the use of questionnaires (non-interventional research).

This study involves the collection of data associated with High Intellectual Potential characteristics, sensory profile, and includes clinical measures such as anxiety anxiety, autistic traits and coping in High Intellectual Potential and control participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * High Intellectual Potential: * Participants with a High Intellectual Potential : Cognitive assessment using the WAIS or WISC-V scale by a psychologist; Intelligence Quotient (IQ) ≥ 130, in the case of a homogeneous cognitive profile, or General Aptitude Index (GAI) \> 130 \[124-134\], in the case of a heterogeneous cognitive profile * Gender and Age: Male or female, aged 18 to 65 * Consent: Free, informed, and written consent (e-CRF) * Control : * Gender and Age: Male or female, aged 18 to 65 * Consent: Free, informed, and written consent (e-CRF) Exclusion Criteria: * High Intellectual Potential: * History or declared psychiatric disorder (characterized depressive episode, personality disorder, addiction, eating disorder, bipolar disorder, obsessive-compulsive disorder) * Neurodevelopmental disorders (autism spectrum disorder, attention deficit and hyperactivity disorder , developmental coordination disorder) * Sensory disability * Subjects under guardianship or curatorship * Pregnant or breast-feeding women * Control : * Presence of High Intellectual Potential known * Presence of intellectual development disorder * History or declared psychiatric disorder (characterized depressive episode, personality disorder, addiction, eating disorder, bipolar disorder, obsessive-compulsive disorder) * Neurodevelopmental disorders (autism spectrum disorder, attention deficit and hyperactivity disorder , developmental coordination disorder) * Sensory disability * Subjects under guardianship or curatorship * Pregnant or breast-feeding women

Primary outcome measure(s)

  • Sensory profile from the Adolescent and Adult Sensory Profile according to each group. — At enrollment
    Sensory profile scores is obtained using the self-report questionnaire Adolescent and Adult Sensory Profile (AASP) after the participant has been included in the study. Subscores for sensory sensitivity, low registration, sensation seeking, and sensation avoidance are collected. For each subscore, the minimum and maximum values range from 15 to 75. A high score indicates high sensory sensitivity.

Trial sites (1)

FacilityCityRegionStatus
Esquirol Hospital Center Limoges New Aquitaine Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07072455 on ClinicalTrials.gov ↗ ← All trials in France